Skip to main content

Prevention of Recurrent Respiratory Tract Infections in Children Using a Ribosomal Immunotherapeutic Agent

A Clinical Review

Pediatric Drugs volume 8, pages 235–243 (2006)Cite this article

Abstract

Recurrent respiratory tract infections (RRTIs) in children constitute a serious problem worldwide. Some children experience considerable morbidity as a result of RRTIs and receive repeated courses of antibacterials that are not effective against viral infectious agents and can increase bacterial resistance. Furthermore, the direct and indirect costs of RRTIs to the community are substantial.

In this article, we review the available clinical evidence relating to use of the bacterial immunostimulant Ribomunyl® for the prevention of RRTIs in children. The product is composed of ribosomal fractions from four bacteria involved in RRTIs as well as a membrane fraction from one of these bacteria (Klebsiella pneumoniae). Ribomunyl® stimulates production of specific humoral and secretory antibodies against the four bacterial strains included in the compound. The product also stimulates non-specific immunity. Thus, Ribomunyl® stimulates both the innate and acquired immune systems and offers preventive efficacy against both bacterial and viral infections.

To perform this review, we searched the MEDLINE database for articles on Ribomunyl® and then included only those publications that described placebo-controlled studies, complied with Good Clinical Practice standards, used the product in official registered indications, and administered it at the recommended dosages. In this way, we were able to generate a comprehensive profile of use of the product and draw valid conclusions about its clinical role.

In clinical trials of children, Ribomunyl® reduced the number of upper or lower RRTIs, the primary outcome measures. Other favorable results relating to efficacy parameters that served as secondary outcome measures in these studies included a reduction in antibacterial treatments, shorter duration of recurrent episodes, reduced need for other medications such as expectorants, smaller number of lost school days or parent absenteeism from work, less fever, and reduced hearing loss. Studies focusing on particular conditions, such as otitis media, or those that included specific patient groups, such as very young children, reported similar findings. Adverse events occurred very rarely and were mild. Their frequency was similar to that reported in placebo groups, and consisted mostly of fever, otorhinolaryngologic symptoms, and cutaneous events.

In conclusion, this review clearly demonstrated that Ribomunyl® is effective in preventing upper and lower RRTIs in children. Ribomunyl® provided a reduction in the number, duration, and severity of infectious episodes and, thereby, reduced antibacterial use and the likelihood of consequent development of bacterial resistance. Ribomunyl® also decreased absence from work or school, which has important economic consequences.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. McCutcheon H, Fitzgerald M. The public health problem of acute respiratory illness in childcare. J Clin Nurs 2001; 10(3): 305–10

    PubMed  Article  CAS  Google Scholar 

  2. Paradise JL, Rockette HE, Colburn DK, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99(3): 318–35

    PubMed  Article  CAS  Google Scholar 

  3. Teele DW, Klein JO, Rosner B, et al. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989; 160(1): 83–94

    PubMed  Article  CAS  Google Scholar 

  4. Wald ER, Guerra N, Byers C. Upper respiratory tract infections in young children: duration of and frequency of complications. Pediatrics 1991; 87(2): 129–33

    PubMed  CAS  Google Scholar 

  5. Wald ER. Sinusitis in infants and children. Ann Otol Rhinol Laryngol 1992; 155: 37–41

    CAS  Google Scholar 

  6. Bhave SY. Approach to recurrent respiratory infections. Indian J Pediatr 2000; 68Suppl. 2: 26–32

    Google Scholar 

  7. Bellanti JA. Recurrent respiratory tract infections in paediatric patients. Drugs 1997; 54Suppl. 1: 1–4

    PubMed  Article  Google Scholar 

  8. Brook I, Grober AE. Dynamics of nasopharyngitis in children. Otolaryngol Head Neck Surg 2000; 122: 696–700

    PubMed  Article  CAS  Google Scholar 

  9. Graham MH. The epidemiology of acute respiratory infections in children and adults: a global perspective. Epidemiol Rev 1990; 120: 149–78

    Google Scholar 

  10. Banz K, Thomas AM, Olivieri D. Economic evaluation of ribosomal immunotherapy in patients with chronic ENT and respiratory tract infections: results for Italy. BioDrugs 1998; 10(5): 385–96

    PubMed  Article  CAS  Google Scholar 

  11. Brook I, Shak K. Bacteriology of adenoids and tonsils in children with recurrent adenotonsillitis. Ann Otol Rhinol Laryngol 2001; 110: 844–8

    PubMed  CAS  Google Scholar 

  12. Gehanno P, Barry B, Bingen E, et al. Microbiology of otitis media in the Paris, France, area from 1987 to 1997. Pediatr Infect Dis J 2001; 20: 570–3

    PubMed  Article  CAS  Google Scholar 

  13. International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. Allergy 1994; 49(19): 1–34

    Google Scholar 

  14. De Martino M, Vierucci A. Il bambino con infezioni respiratorie ricorrenti. Immunol Pediatr 1981; 1: 76–9

    Google Scholar 

  15. World Health Organization. GBD 2000: YLLs by age, sex and cause for the year 2000 [online]. Available from URL: http://www.who.int/healthinfo/gbdwhore-gionll2000v2/xls [Accessed 2006 Jul 27]

  16. Eisen DP. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis 2003; 37: 1496–505

    PubMed  Article  CAS  Google Scholar 

  17. Soderstrom M. Respiratory tract infections in children with recurrent episodes as preschoolers. Acta Paediatr Scand 1991; 80: 688–95

    PubMed  Article  CAS  Google Scholar 

  18. Hoberman A, Marchant CD, Kaplan SL, et al. Treatment of acute otitis media consensus recommendations. Clin Pediatr (Phila) 2002; 41: 373–90

    Article  Google Scholar 

  19. Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 2005; 11: 4–16

    PubMed  Article  CAS  Google Scholar 

  20. Gillis LM, White HD, Whitehurst A, et al. Vancomycin-tolerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999–2001. Am J Med Sci 2005; 330(2): 65–8

    PubMed  Article  Google Scholar 

  21. Akins RL, Haase KK. Gram-positive resistance: pathogens, implications, and treatment options: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2005; 25(7): 1001–10

    PubMed  Article  CAS  Google Scholar 

  22. Lambert S. The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Commun Dis Intell 2004; 28: 510–6

    PubMed  Google Scholar 

  23. Leder K, Sinclair MI, Mitakakis TZ, et al. A community-based study of respiratory episodes in Melbourne. Aust N Z J Public Health 2003; 27: 399–404

    PubMed  Article  Google Scholar 

  24. Leder K. Respiratory illness during winter: a cohort study of urban children from temperate Australia. J Paediatr Child Health 2005; 41: 125–9

    Article  Google Scholar 

  25. Youmans AS, Youmans GP. Immunogenic activity of a ribosomal fraction obtained from Mycobacterium tuberculosis. J Bacteriol 1965; 89: 1291–8

    PubMed  CAS  Google Scholar 

  26. Data on file, Pierre Fabre Medicament

  27. Nikolaeva LV, Savelev EP. Molecular-biological and immunological properties of ribosomal vaccines. Biomed Sci 1991; 2(1): 1–10

    PubMed  CAS  Google Scholar 

  28. Levenson VJ, Mallett CP, Hale TL. Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect Immun 1995; 63(7): 2762–5

    PubMed  CAS  Google Scholar 

  29. Faure GC, Bene MC, Simon C, et al. Increase in specific antibody-forming cells in human tonsils after oral stimulation with D-53, a ribosomal vaccine. Int J Immunopharmacol 1990; 12(3): 315–20

    PubMed  Article  CAS  Google Scholar 

  30. Zanin C, Perrin P, Bene MC, et al. Antibody-producing cells in peripheral blood and tonsils after oral treatment of children with bacterial ribosomes. Int J Immunopharmacol 1994; 16(7): 497–505

    PubMed  Article  CAS  Google Scholar 

  31. Faure G, Béné MC. Use of bacterial ribosomal immunostimulators in respiratory tract infections. Clin Immunother 1995; 4: 138–46

    Article  Google Scholar 

  32. Kolopp-Sarda MN, Bene MC, Allaire JM, et al. Kinetics of specific salivary IgA responses in man after oral challenge by ribosomal immunostimulant. Int J Immunopharmacol 1997; 19(3): 181–6

    PubMed  Article  CAS  Google Scholar 

  33. Caliot E, Libon C, Kerneis S, et al. Translocation of ribosomal immunostimulant through an in vitro-reconstituted digestive barrier containing M-like cells. Scand J Immunol 2000; 52(6): 588–94

    PubMed  Article  CAS  Google Scholar 

  34. Lafont S, Millet I, Kouassi E, et al. Induction of murine B cell proliferation and immunoglobulin synthesis by some bacterial ribosomes. Microbiol Immunol 1988; 32(10): 1043–58

    PubMed  CAS  Google Scholar 

  35. Maccario R, De Amici M, Montagna D, et al. Evaluation of immune response after stimulation with bacterial ribosomal extracts: B, T, and NK lymphocyte functions. Adv Otorhinolaryngol 1992; 47: 332–7

    PubMed  CAS  Google Scholar 

  36. Roques C, Frayret MN, Luc J, et al. Effect of an in vivo immunostimulant treatment on PMN functions: interactions with antibiotics in vitro. Int J Immunopharmacol 1991; 13(8): 1051–7

    PubMed  Article  CAS  Google Scholar 

  37. Roques C, Frayret MN, Luc J, et al. Immunostimulant effects on granulocyte functions during an acute respiratory infection. Dev Biol Stand 1992; 77: 183–7

    PubMed  CAS  Google Scholar 

  38. Kantar A, Oggiano N, Romagnoni GG, et al. Effect of oral administration of bacterial extracts on the bactericidal capacity of polymorphonuclear leucocytes in children with recurrent respiratory infections. J Int Med Res 1991; 19(6): 451–6

    PubMed  CAS  Google Scholar 

  39. Hbabi L, Roques C, Michel G, et al. In vitro stimulation of polymorphonuclear cell adhesion by Ribomunyl, and antibiotic plus Ribomunyl combinations: effects on CD18, CD35 and CD16 expression. Int J Immunopharmacol 1993; 15(12): 163–73

    PubMed  Article  CAS  Google Scholar 

  40. Hbabi-Haddioui L, Roques C. Inhibition of Streptococcus pneumoniae adhesion by specific salivary IgA after oral immunisation with a ribosomal immunostimulant. Drugs 1997; 54Suppl. 1: 29–32

    PubMed  Article  CAS  Google Scholar 

  41. Spisek R, Brazova J, Bartunkova J. Maturation of dendritic cells by bacterial immunomodulators. Vaccine 2004; 22: 2761–8

    PubMed  Article  CAS  Google Scholar 

  42. Balbi B, Aufiero A, Pesci A, et al. Lower respiratory tract inflammation in chronic bronchitis: evaluation by bronchoalveolar lavage and changes associated with treatment with Immucytal, a biological response modifier. Chest 1994; 106(3): 819–26

    PubMed  Article  CAS  Google Scholar 

  43. Pujol JL, Klein B, Godard P, et al. Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro. Chest 1991; 100(3): 644–5

    PubMed  Article  CAS  Google Scholar 

  44. Sironi M, Sica A, Riganti F, et al. Interleukin-6 gene expression and production induced in human monocytes by membrane proteoglycans from K. pneumoniae. Int J Immunopharmacol 1990; 12(4): 397–402

    PubMed  Article  CAS  Google Scholar 

  45. Luini W, De Rossi M, Licciardello L, et al. Chemotactic cytokine gene expression and production induced in human monocytes by membrane proteoglycans from K. pneumoniae. Int J Immunopharmacol 1991; 13(6): 631–7

    PubMed  Article  CAS  Google Scholar 

  46. Bystron J, Hermanova Z, Szotkovska J, et al. Effect of ribosomal immunotherapy on the clinical condition and plasma levels of cytokines: IL-4, IL-5, IL-12, IFN, and total IgE, in patients with seasonal allergy during the pollen season. Clin Drug Invest 2004; 24: 761–4

    Article  CAS  Google Scholar 

  47. Allavena P, Erroi A, Pirelli A, et al. Stimulation of cytotoxic and non-cytotoxic functions of natural killer cells by bacterial membrane proteoglycans and ribosomes. Int J Immunopharmacol 1989; 11(1): 29–34

    PubMed  Article  CAS  Google Scholar 

  48. Chalifour A, Jeannin P, Gauchat JF, et al. Direct bacterial protein PAMPs recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood 2004; 104: 1778–83

    PubMed  Article  CAS  Google Scholar 

  49. Bellanti JA, Olivieri D, Seranno E. Ribosomal immunostimulation: a review evaluating its clinical relevance in prevention of upper and lower respiratory tract infections in children and adults. BioDrugs 2003; 17: 355–67

    PubMed  Article  CAS  Google Scholar 

  50. Michel FB, Dussourd D’Hinterland L, Bousquet J, et al. Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans. Infect Immun 1978; 20(3): 760–9

    PubMed  CAS  Google Scholar 

  51. Clot J. Pharmacology of ribosomal immunotherapy. Drugs 1997; 54Suppl. 1:33–6

    PubMed  Article  CAS  Google Scholar 

  52. Giovannini M, Fiocchi A, Sala M, et al. Immucytal in the prevention and treatment of recurrent upper respiratory tract infections in children: a randomized, placebo-controlled, double blind study. Int J Immunother 2000; 16: 67–75

    CAS  Google Scholar 

  53. Mora R, Barbieri M, Passali GC, et al. A preventive measure for otitis media in children with upper respiratory tract infections. Int J Pediatr Otorhinolaryngol 2002; 63: 111–8

    PubMed  Article  CAS  Google Scholar 

  54. Hoffman JA. The effect of bacterial ribosomes extracts on clinical and immunological parameters in children with recurrent infections of respiratory tract with bronchospastic symptoms [abstract no. 616]. XXI Congress of EAACI; 2002 Jun 1–5; Naples

  55. Vautel JM, Cauquil J, Perruchet AM, et al. Prevention of recurrent ear, nose and throat infections in young children with Ribomunyl: double-blind, placebo-controlled study. Curr Ther Res 1993; 53: 722–9

    Article  Google Scholar 

  56. Lacomme Y, Narcy P. Prévention par immunothérapie ribosomale des épisodes de surinfection récidivante de la sphère ORL chez l’enfant: résultats cliniques d’une étude multicentrique. Immunol Med 1985; 11: 73–5

    Google Scholar 

  57. Castel Y. Prévention des récidives infectieuses des voies respiratoires chez l’enfant par Ribomunyl comprimés. Immunol Med 1986; 14: 34–40

    Google Scholar 

  58. Haguenauer JP. Prévention des épisodes infectieux récidivants de la sphère O.R.L. par Ribomunyl comprimés chez l’enfant de moins de 5 ans. Immunol Med 1987; 18: 36–9

    Google Scholar 

  59. Palma-Carlos G, Trindade MF, Azevedo-Conde T. Oral immunotherapy with bacterial extract versus ribosomal extracts adjuved with membrane proteoglycans: clinical efficacy. Clin Exp Allergy 1990; 20: 12–6

    Google Scholar 

  60. Fiocchi A, Baldini G, Giovannini M, et al. Bacterial ribosomal and Klebsiella cell wall extract treatment of recurrent respiratory infections in childhood. Eur Respir J 1990; 9: 388–94

    Google Scholar 

  61. Hüls G, Hirche H, Lindemann H. Klinische effizienz eines neuen multibakteriellen immunth (Ribomunyl) bei kindern und jugendlichen mit rezidivierenden respiratorischen infekten. Jatros Paediatrie 1991; 7: 1–14

    Google Scholar 

  62. Alfarro C. Prévention des récidives infectieuses ORL et bronchopulmonaires chez l’enfant par Ribomunyl sachet: résultat d’un essai clinique multicentrique au Portugal. Med Dig 1995; 11(5): 1–8

    Google Scholar 

  63. Wronski W. Role of ribosomal immunotherapy in the prevention of respiratory infections in children. Drugs 1997; 54Suppl. 1: 15–9

    Google Scholar 

  64. Belaeva L. Clinical experience with ribosomal immunotherapy in paediatrics in Belarus. Drugs 1997; 54Suppl. 1: 47–9

    Google Scholar 

  65. Debas J. Ribosomal immunostimulation in the prevention of recurrent amygdalitis: a multicentre study in Argentina. Drugs 1997; 54Suppl. 1: 26–9

    Google Scholar 

  66. Serrano E, Demanez JP, Morgon A, et al. Effectiveness of ribosomal fractions of Kp, Spn, Spyo, Hinf and the memb fraction of Kp (Ribomunyl) in the prevention of recurrences of infectious rhinitis: results of a multicenter double-blind placebo-controlled study. Eur Arch Otorhinolaryngol 1997; 254: 372–5

    PubMed  Article  CAS  Google Scholar 

  67. Boyle P, Bellanti JA, Robertson C. Meta-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl) in prevention of respiratory infections. BioDrugs 2000; 14(6): 389–408

    PubMed  Article  CAS  Google Scholar 

  68. Gramiccioni E, Girbino G, Pelucco D. Efficacy and tolerability of Immucytal in the prevention of upper respiratory tract infections: a randomised, placebo-controlled, double-blind study. J Clin Research 2001; 4: 53–63

    Google Scholar 

  69. Castaneda JL, Chavez RR. Estudio de eficacia de prevencion de 3 meses con derivados ribosomales en ninos con IRR. Rev Enferm Infec 2002; 15: 60–6

    Google Scholar 

  70. Mora R, Ralli G, Passali FM, et al. Short ribosomal prophylaxis in the prevention of clinical recurrences of chronic otitis media in children. Int J Ped Orl 2003; 3267: 1–7

    Google Scholar 

  71. Portales P, Clot J. Immunostimulants revisited: focus on the pharmacology of Ribomunyl. BioDrugs 2006; 20(2): 81–4

    PubMed  Article  CAS  Google Scholar 

  72. Elies W, Pletan Y. An international medico-economic survey of 2007 children with recurrent nasopharyngitis and acute otitis media. Drugs 1997; 54Suppl. 1: 5–12

    PubMed  Article  Google Scholar 

  73. Banz K, Schwicker D, Thomas AM. Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections. Pharmacoeconomics 1994; 6(5): 464–77

    PubMed  Article  CAS  Google Scholar 

  74. Schwarz B, Dangl-Neugaard B. An economic analysis using ribosomal immunotherapy to treat children with recurrent upper respiratory tract infections. Clin Drug Invest 1997; 14(3): 206–10

    Article  CAS  Google Scholar 

  75. Berdeaux G, Hervie C, Marquis P, et al. Parental quality of life and recurrent ENT infections in their children: development of a questionnaire. Qual Life Res 1998; 7: 501–12

    PubMed  Article  CAS  Google Scholar 

  76. Van Cauwenberge P, Berdeaux G, Morineau A, et al. Use of diagnosis clusters to assess the economic consequences of rhinopharyngitis in children in Italy and France during the winter. Clin Ther 1999; 21(2): 404–21

    PubMed  Article  Google Scholar 

Download references

Acknowledgments

The authors thank Pierre Fabre Medicament for assistance in supplying documentation. No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Affiliations

  1. Respiratory Diseases Department, A. de Villeneuve Hospital, Montpellier, France

    Jean Bousquet

  2. Department of Paediatrics and Maternal Medicine, The Melloni Hospital, 52 Via Melloni, Milan, 20131, Italy

    Alessandro Fiocchi

Authors
  1. Jean Bousquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Fiocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bousquet, J., Fiocchi, A. Prevention of Recurrent Respiratory Tract Infections in Children Using a Ribosomal Immunotherapeutic Agent. Pediatr-Drugs 8, 235–243 (2006). https://doi.org/10.2165/00148581-200608040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00148581-200608040-00003

Keywords

  • Otitis Medium
  • Sick Leave
  • Acute Otitis Medium
  • Moraxella Catarrhalis
  • Infectious Episode